bypass surgery News
-
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to prevent, treat and diagnose diseases of unmet clinical need, announced today that it has received notice of allowance for foundational patent applications for two of its core technologies in several key markets further strengthening the company’s intellectual ...
-
tiakis receives GLP Certificate from Competent Authority
tiakis BIOTECH AG today announced that the competent Good Laboratory Practice (GLP) Monitoring Authority of the German State of Schleswig-Holstein (State Office for Agriculture, Environment and Rural Areas of the Land Schleswig-Holstein) has performed a GLP inspection resulting in the confirmation that tiakis test site is able to conduct the archiving of documents related to in-house development ...
-
World Leading Cardiac Specialists Join Celixir Scientific Advisory Board To Form Innovative Cardiovascular Medicines Collaboration
Celixir (formerly Cell Therapy Limited) today announced the formation of the Innovative Cardiovascular Medicines Collaboration. The Collaboration includes world-leading expertise in cardiac research and clinical development, with the purpose of better understanding the basis for cardiac regeneration. The Collaboration will be jointly led by Professor Kim Fox, Consultant Cardiologist and ...
By Celixir plc
-
tiakis (formerly Proteo Biotech AG) Elafin Enters the Clinic For Subcutaneous Use In Pulmonary Arterial Hypertension
tiakis BIOTECH AG today announced the start of the clinical development for the subcutaneous use of tiakis lead investigational drug candidate Elafin (INN: Tiprelestat). The Duke University Early Phase Research Unit initiated the recruitment of healthy individuals for the Phase I clinical trial in the U.S. to assess the safety and tolerability of repeated single doses of Elafin. tiakis research ...
-
Marizyme Announces Approval for DuraGraft in India
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is now registered and licensed for import into India through Marizyme's distribution partner Regency Lifesciences. India ...
-
Celixir Partners with TMC Life Sciences Bhd and Thomson to Change the Standard of Medical Care for Patients in Southeast Asia
Celixir (formerly Cell Therapy Limited) has recently announced a partnership with TMC Life Sciences Bhd (TMCLS) and its associated company, Thomson Medical (Thomson) to accelerate the discovery and development of life-changing and lifealtering regenerative medicines. Under the terms of the Memoranda of Understanding (MOU), Celixir will develop educational programmes to train medical professionals ...
By Celixir plc
-
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has entered into a supply and distribution agreement with Abdera Financial, Inc., a Chilean based distributor, to distribute Marizyme's DuraGraft® ...
-
Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors. "Ms. Kampf will provide invaluable guidance as an ...
-
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and diagnose diseases of unmet clinical need announced today that results of the GOAL Study (Vienna Heart Center Floridsdorf/PI Dr. Winkler Bernhard) were presented by Dr. Maximillian Y. Emmert (German Heart Center and Charite Universitatsmedizin, Berlin Germany) Friday, ...
-
`Bilirubin` to eliminate inflammation... Vilix, the world`s first pharmaceutical drug
Bilirubin, which causes jaundice in humans, has been in the spotlight as an anti-inflammatory substance since the 1930s. The phenomenon that rheumatoid inflammation disappears when a patient with rheumatoid arthritis suffers from jaundice was discovered by Philip Hench, a professor at the Mayo Clinic in the United States, who was awarded the Nobel Prize in Physiology or Medicine. Attempts to drug ...
-
Cell Therapy Ltd Grants Japan License To Daiichi Sankyo for Its Heart Regeneration Medicine, Heartcel
Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel (immuno-modulatory progenitor [iMP] cells) to Daiichi Sankyo. Daiichi Sankyo will undertake all development, regulatory and commercial activities for iMP cells in the territory of Japan only, while CTL retains its worldwide rights outside of Japan as well as global ...
By Celixir plc
-
The next evolution in blood vessel occlusion
The good news for his patient was that she was young. A lower extremity bypass procedure - like any surgery - can be more difficult as we age. The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries in the leg - were unusable. The patient had undergone varicose vein treatments as a young woman that ...
-
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme. In his role Mr. Barthel will look to advance the Company’s technology pipeline and stay committed to the commercialization efforts of DuraGraft in Europe and Asia while focusing on the FDA submissions for ...
-
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in ...
-
Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. Roger Schaller has been appointed Executive Vice President (EVP) of Commercial ...
-
BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia
BioCardia, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina. These patients experience ...
-
Bisphenol A exposure can increase risk of diabetes and heart attacks
In human fat tissues, bisphenol A (BPA) suppresses levels of a key hormone, adiponectin, that protects people from heart attacks and Type II diabetes. These results implicate BPA as a potential cause of metabolic syndrome, one of the most serious and costly public health problems in the US. Most Americans have levels of BPA within their serum within the range of concentrations sufficient to ...
-
Celixir announces US FDA approval of the IND application for cell therapy Heartcell
FDA IND and UK MHRA CTA approval both achieved in H1 2018 Potentially pivotal heart failure trial of up to 250 patients in the UK and US Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for Heartcel, its immune-modulatory ...
By Celixir plc
-
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results in the second half of this year XyloCor ...
-
Potrero Medical Names Vanessa Moll, MD, PhD, FCCM, FASA as Chief Medical Officer
Potrero Medical, innovator of the Accuryn Monitoring System, a sensory integrated foley catheter that provides real-time, actionable information to health care providers so they can take steps to prevent critical conditions such as acute kidney injury (AKI), announced that Vanessa Moll, MD, PhD, FCCM, FASA has joined the executive leadership team as its Chief Medical Officer (CMO). Dr. Moll ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you